1. Market Research
  2. > Pharmaceutical
  3. > Biopharmaceutical Market Trends
Cell Therapy Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Therapy Type ; Product ; Technology ; Application ; End User, and Geography

Cell Therapy Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Therapy Type ; Product ; Technology ; Application ; End User, and Geography

  • January 2021
  • 201 pages
  • ID: 6027528
  • Format: PDF
  • The Insight Partners
Up to $1700 off Until Apr 20th 2021


Table of Contents

Search Inside

The global cell therapy market is expected to reach US$ 12,563.23 million by 2027 from US$ 7,260.50 million in 2019. The market is estimated to grow at a CAGR of 7.2% from 2020–2027. The growth of the market is attributed to increasing prevalence of chronic diseases, rising adoption of regenerative medicines, and surging number of approvals for cell-based therapies. However, the high cost of cell therapy manufacturing hinders the growth of the market.
Cell therapy is a procedure where living and intact cells are injected, implanted, or grafted into the patient’s body.This technology relies on replacing dysfunctional cells with healthy functioning ones.

Cells mainly used for such advanced therapies are stem cells, as they have ability to differentiate into the specific cells required for repairing damaged or defective tissues or cells. Moreover, cell therapy has applications in the development of regenerative medicines.
The biotechnology sector in Asia Pacific is proliferating with the support of heavy investments and strategic developments between private and public organizations. For instance, in December 2019, Astellas Pharma Inc. (Japan) signed an agreement to acquire Audentes Therapeutics Inc., a gene therapy company, for US$ 3 billion. Similarly, in November 2019, Fujifilm invested ~US$ 120 million (JPY 13 billion) in gene therapy as a part of the contract development and manufacturing segment of the organization. In addition, the Japan Pharmaceutical Medical Device Agency approved two gene therapy products. The products were approved simultaneously under Sakigake designation, which is equivalent to the FDA breakthrough therapy designation and the EMA Priority Medicine (PRIME) designation and is expected to approve at least one therapy per year.
Such strategic developments by the domestic players in the Asian countries for the cell therapy domain are likely to increase the demand for cell therapy in the coming future.Since the approval of Gendicine for the treatment of head-and-neck squamous cell carcinoma by substituting affected copies of the p53 tumor suppressor gene with normal gene copies, China has expanded cell therapy applications and increased cell therapy production.

Rising awareness about cell therapy is allowing the increase in adoption of cell therapies in Asia Pacific.For instance, in 2018, Taiwan held the ninth position for a regulatory agency to approve cell therapy’s clinical application.

In January 2020, the country introduced six autologous cell therapy treatments, which include two for cancer, two for skin cell transplantation, and two for bone and cartilage regeneration.In Taiwan, four hospitals have licenses to provide cell therapies, and 26 more hospitals have already applied for a license to provide cell therapies.

Furthermore, regenerative medicine research in cell therapy, gene therapy, and tissue engineering is rapidly growing in Asia Pacific countries. Also, rise in geriatric population; increase in developments in healthcare services; surge in requirement for transplants; and emergence of personalized medicines in Japan, China, India, and South Korea would create demand for cell therapies in the coming years. This is likely to offer various growth opportunities for the market players during the forecast period.
The cell therapy market, based on therapy type, is bifurcated into allogeneic and autologous.In 2019, the allogeneic segment accounted for a larger share owing to the availability of substantial number of approved products for clinical use.

For instance, in 2018, Alofisel developed by TiGenix (Takeda) is the first allogeneic stem cell-based therapy approved for use in Europe.
The COVID-19 outbreak was first reported in Wuhan (China) in December 2019.The pandemic is causing massive disruptions in supply chains, consumer markets, and economy across the world.

As the healthcare sector is focusing on saving lives of COVID-19 patients, the demand for cell therapy is reducing worldwide.
The International Society of American College of Cardiology (ACC), World Health Organization (WHO), European Union (EU), Organization for Economic Co-operation and Development, Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), Ministry of Health and Prevention (MoHAP), and US Food and Drug Administration (FDA) are a few of the prime secondary sources referred to while preparing the report on the cell therapy market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Middle East and Africa Cell Therapy Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Therapy Type ; Product ; Technology ; Application ; End User and Country

  • $ 3000
  • February 2021
  • 129 pages

The Middle East and Africa cell therapy market is expected to reach US$ 346.7 million by 2027 from US$ 234.4 million in 2019; it is anticipated to grow at a CAGR of 5.1% during 2019-2027. The Middle East ...

  • Middle East
  • Africa
  • Cell Therapy
  • Industry analysis
  • Chronic Disease Prevalence
  • Diabetes Prevalence


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on